Adage Capital Partners Gp, L.L.C. Contrafect Corp Transaction History

Adage Capital Partners Gp, L.L.C.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2020 Aug 14, 2020	BUY	$4.69 - $7.81 $1.7 Million - $2.83 Million	362,000 Added 125.69%	650,000 $4.15 Million
Q1 2020 May 15, 2020	BUY	$5.5 - $12.3 $1.58 Million - $3.54 Million	288,000 New	288,000 $1.66 Million

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.